Smith & Nephew plc (GB:SN)
LSE:SN
Want to see GB:SN full AI Analyst Report?
SN Stock Chart & Stats
1268.00 p
7.80 p(0.79%)
At close: 4:00 PM EST
1268.00 p
7.80 p(0.79%)
Day’s Range― - ―
52-Week Range1,050.00 p - 1,441.50 p
Previous CloseN/A
Volume71.06K
Average Volume (3M)3.93M
Market Cap
£9.42B
Enterprise Value15.53B
Total Cash (Recent Filing)£557.20M
Total Debt (Recent Filing)£3.33B
Price to Earnings (P/E)19.9
Beta1.08
Next Earnings
Aug 04, 2026EPS Estimate
0.35Next Dividend Ex-DateN/A
Dividend Yield2.35%
Share Statistics
EPS (TTM)0.74
Shares Outstanding846,457,640
10 Day Avg. Volume2,834,900
30 Day Avg. Volume3,927,868
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)2.73
Price to Sales (P/S)2.30
P/FCF Ratio16.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£1,407.50Price Target Upside11.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)1.11
Revenue Forecast (FY)£6.58B
Bulls Say, Bears Say
Bulls Say
Diversified Product Mix & Recurring ConsumablesSmith & Nephew sells a broad set of implants, procedure devices and wound-care consumables across three businesses. That diversification and recurring consumable demand (dressings, single-use disposables) reduces reliance on any single therapy and supports steadier revenue and procedure-driven cash flows over multi-year horizons.
Innovation-led Growth And Product PipelineA heavy share of recent growth derives from recent launches and management plans many new introductions. Sustained innovation gives durable competitive advantage: faster adoption, higher share in procedure growth, and better pricing/pull-through for consumables, supporting mid-term revenue CAGR assumptions if launches continue to gain clinical traction.
Material Improvement In Cash GenerationCash generation has strengthened significantly, enabling reinvestment, targeted share buybacks and dividend increases while keeping leverage manageable. Higher and more consistent FCF supports funding for R&D, bolt-on M&A integration, and the company's medium-term ROIC and FCF targets without immediate strain on the balance sheet.
Bears Say
China VBP Procurement PressureVolume-based procurement in China is a structural policy-driven program that compresses margins and pricing in that market. While China is a small share of sales (~2%), the program reduces profit contribution and demonstrates exposure to government procurement policies that can persist and slow regional growth and margin recovery.
CMS Reimbursement Changes Hitting Skin-substitutesRegulatory reimbursement shifts in the U.S. for skin substitutes materially lower unit economics for that product cohort. This structural change reduces recurring revenue and operating profit in Advanced Wound Management until product mix, channel strategy or payer policies adjust, and represents an ongoing headwind to segment margins in the medium term.
Margin Volatility And Near-term Extraordinary HeadwindsDespite margin improvement in 2025, multi-year margin and return inconsistency remains a concern. Material 2026 items (higher tariffs, inventory write-downs/revaluations and acquisition dilution) create execution risk to sustaining margin expansion and achieving medium-term ROIC/FCF targets, increasing sensitivity to operational delivery.
Smith & Nephew News
SN FAQ
What was Smith & Nephew plc’s price range in the past 12 months?
Smith & Nephew plc lowest share price was 1050.00 p and its highest was 1441.50 p in the past 12 months.
What is Smith & Nephew plc’s market cap?
Smith & Nephew plc’s market cap is £9.42B.
When is Smith & Nephew plc’s upcoming earnings report date?
Smith & Nephew plc’s upcoming earnings report date is Aug 04, 2026 which is in 40 days.
How were Smith & Nephew plc’s earnings last quarter?
Smith & Nephew plc released its earnings results on Mar 02, 2026. The company reported 0.441 p earnings per share for the quarter, beating the consensus estimate of 0.432 p by 0.009 p.
Is Smith & Nephew plc overvalued?
According to Wall Street analysts Smith & Nephew plc’s price is currently Undervalued.
Does Smith & Nephew plc pay dividends?
Smith & Nephew plc pays a Semiannually dividend of 17.78 p which represents an annual dividend yield of 2.35%. See more information on Smith & Nephew plc dividends here
What is Smith & Nephew plc’s EPS estimate?
Smith & Nephew plc’s EPS estimate is 0.35.
How many shares outstanding does Smith & Nephew plc have?
Smith & Nephew plc has 846,457,640 shares outstanding.
What happened to Smith & Nephew plc’s price movement after its last earnings report?
Smith & Nephew plc reported an EPS of 0.441 p in its last earnings report, beating expectations of 0.432 p. Following the earnings report the stock price went down -4.265%.
Which hedge fund is a major shareholder of Smith & Nephew plc?
Currently, no hedge funds are holding shares in GB:SN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Smith & Nephew Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
£1,407.50 (11.00% Upside)
£1,407.50 (11.00% Upside)
Insider Transactions
Sold Shares
Worth £3.1M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
23.23%
12-Months-Change
Fundamentals
Return on Equity
11.79%
Trailing 12-Months
Asset Growth
-5.96%
Trailing 12-Months
Company Description
Smith & Nephew plc
Smith & Nephew plc, along with its subsidiaries, operates globally as a developer, manufacturer, marketer, and seller of medical technology. Its orthopaedic division offers knee implants for replacement procedures and hip implants for joint reconstruction. This segment also provides trauma and extremities products, including internal and external fixation devices crucial for stabilizing severe fractures and correcting deformities. In the sports medicine field, the company furnishes surgeons with comprehensive joint repair solutions. These encompass specialized instruments, advanced technologies, and implants necessary for minimally invasive joint surgeries, addressing soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. Additionally, its arthroscopic enabling technologies support surgical visualization and intervention inside joints, comprising fluid management equipment, high-definition cameras, digital image capture systems, scopes, light sources, and monitors. It also supplies radiofrequency, electromechanical, and mechanical tissue resection devices, along with hand instruments for removing damaged tissue, and provides ear, nose, and throat (ENT) solutions. Furthermore, Smith & Nephew delivers sophisticated advanced wound management solutions. This category features products for the treatment and prevention of acute and chronic wounds, including leg, diabetic, and pressure ulcers, burns, and post-operative wounds. Its offerings extend to advanced wound bioactives, incorporating biologics and other active technologies for debridement, dermal repair, and regeneration, as well as regenerative medicine products like skin, bone graft, and articular cartilage substitutes. The advanced wound devices portfolio includes traditional and single-use negative pressure wound therapy systems, alongside hydrosurgery devices. Primarily serving healthcare providers, Smith & Nephew plc was founded in 1856 and maintains its corporate headquarters in Watford, United Kingdom.
SN Stock 12 Month Forecast
Average Price Target
1,407.50 p
▲(11.00% Upside)
Technical Analysis
Advanced Medical Solutions
―
ConvaTec
―
Hikma Pharmaceuticals
―
PureTech Health
―
Spire Healthcare
―
Options Prices
Currently, No data available
---